Starpharma (ASX:SPL) is an international biopharmaceutical company based in Australia. It develops pharmaceutical and medical products based on proprietary polymers named “dendrimers”. The federal government’s Medical Research Futures Fund (MRFF) and MTPConnect supported a BTB (Biomedical Translation Bridge) program in which she participated.
The company has developed an antiviral nasal spray named VIRALEZE for COVID-19, the effect of which proved to be rapid and considerable. The spray acts on a rather broad viral spectrum. It could therefore be used during the appearance of future pandemics. Thanks to this, Starpharma (ASX:SPL) won the price of “Most Significant Business Outcome”.
VIRALEZE, accessible in several countries
VIRALEZE was marketed outside Australia after 12 months. A group of international experts selected Starpharma to participate in the government-funded program in September 2020. The company benefited a million dollar grant to accelerate the development and commercialization of VIRALEZE. Thanks to this, it was able to launch in the UK just 6 months later, in March 2021.
This biotechnology is the first listed on the ASX to have launched on the international market a Covid-19 preventive product. It was national pharmacy chain LloydsPharmacy that first launched the spray in the UK. Starpharma then signed sales and distribution agreements for VIRALEZE in Italy, Vietnam and the Middle East. The product is available online to consumers in Europe, Asia and the Middle East.
“It is pleasing to see the external recognition of the significant development and commercial achievements made possible by the hard work of the Starpharma team in a very short period of time. »
Dr. Jackie Fairley, CEO of Starpharma
The spray would have great potential for use in many settings
According to the company, funding from the MRFF and MTPConnect helped to help develop the nasal spray. It was also used in extensive antiviral testing of VIRALEZE and its main ingredient, SPL7013. Moreover, this broad-spectrum antiviral dendrimer has already proven its ability effectively trap and block many pandemic and endemic viruses.
VIRALEZE is a nasal spray with many benefits. It is innovative, easy to use and cost effective. With its broad-spectrum antiviral activity, it would be helpful during seasonal cold and flu outbreaks. It could even be used during pandemic preparedness.
SOURCE: MIRA NEWS